Bonus Biogroup
Bonus Biogroup
Contact details
Address
Matam Advanced Technology Park, P.O.B 15143
Haifa
Phone
+972-73-206-7104
info@bonus-bio.com
Website
bonus-bio.com
About Bonus Biogroup
Get to know us in depth
Bonus Biogroup (TASE: BONS) is an Israeli clinical-stage biotechnology company developing next-generation regenerative medicine therapies from its headquarters and GMP manufacturing centre in Haifa. Its proprietary platform combines autologous mesenchymal cells, a three-dimensional bioactive mineral scaffold and automated bioreactor growth to produce two lead product candidates - BonoFill, a viable tissue-engineered bone graft, and MesenCure, an allogeneic cell therapy for inflammation and tissue damage.
Company presentation 2025
The full investor deck - technology platform, pipeline, clinical results, GMP manufacturing and the market opportunity behind BonoFill and MesenCure.
Who we are
Bonus Biogroup is an advanced clinical-stage biotechnology company developing therapies for indications in regenerative medicine where treatment options are limited and the unmet need is large: bone loss and skeletal defects, uncontrolled inflammation and tissue damage. The company was founded in 2008 and has built a technology platform that underpins both of its leading candidates rather than a single-product programme.
The vision is stated plainly by the company: to empower millions of patients to live healthier and longer lives through transformative science in regenerative medicine. The mission behind it is to develop safe, effective and affordable tissue engineering and cell therapy products for severe conditions in multi-billion-dollar markets.
The technology platform
Autologous cell sampling
Cells are sampled from the patient in a minimally invasive procedure, professionalised and expanded outside the body before being returned as a living graft.
Proprietary bioreactor system
Automated growth with stringent control of expansion and differentiation conditions, designed for consistency and quality between batches.
3D mineral scaffold
A biocompatible and bioactive three-dimensional scaffold carries the cells and gives the graft its mechanical structure.
Allogeneic expansion & priming
Donor-derived mesenchymal cells are expanded and primed to boost potency without genetic modification - no viral vectors, no gene editing.
Single-donor cell banks
Up to 70,000 patients treatable from one donor bank while staying under 20 population doublings, keeping the cell culture young and potent.
Fresh, ready-to-use formulation
MesenCure is supplied fresh and viable rather than cryopreserved, avoiding the loss of potency that comes with freezing and thawing.
Two lead product candidates
BonoFill™
A personalised, viable tissue-engineered bone graft made of a high-density culture of the patient's own cells on a bioactive mineral scaffold, grown ex vivo in about two weeks. Designed to fit a wide range of defect sizes for maxillofacial, dental and orthopaedic indications, replacing autologous bone harvesting and its associated morbidity.
MesenCure™
An enhanced allogeneic cell therapy from healthy-donor adipose mesenchymal cells, designed to modulate inflammation and promote tissue repair. Lead indication is respiratory distress including ARDS, with preclinical work in cytokine release syndrome and chemotherapy-induced organ injury. Given in up to three intravenous doses.
Clinical milestones
- 2008Bonus Biogroup founded by Dr. Shai Meretzki and a multidisciplinary team of regenerative medicine experts.
- 2013A dedicated manufacturing centre is established to support research and development.
- 2016-17Clinical trials of BonoFill begin for facial and limb bone defects.
- 2021First-in-human study of MesenCure, followed by a 50-patient Phase II in severe COVID-19 respiratory distress.
- 2022New GMP-compliant headquarters and manufacturing centre opens in Haifa, with two dedicated production halls and QC laboratories.
- 2024BonoFill maxillofacial Phase II completed: 90% of transplants met the bone reconstruction endpoint, no treatment-related severe adverse events. Israeli Ministry of Health certifies cGMP manufacturing for Phase III.
- 2025FDA permits a Phase III trial of MesenCure; the protocol is being amended to broaden it to respiratory distress from all causes, including ARDS. BonoFill limb-defect Phase II continues.
- 2026BonoFill Phase III planned in the United States for jaw bone defects, subject to regulatory clearance; interim limb-defect data expected.
In the MesenCure Phase II, patients treated with MesenCure plus standard of care showed a 68% lower mortality rate, a 57% lower need for invasive ventilation and a 38% shorter hospital stay than standard of care alone.
Manufacturing & quality
Leadership
The company is led by founder and CEO Dr. Shai Meretzki, who previously founded Pluristem Therapeutics and holds a Ph.D. in Biotechnology from the Technion, together with Executive Chairman Yossi Rauch, formerly chief economist of Leumi PIA. The management team combines R&D, GMP production, regulatory and clinical operations experience: Dr. Dror Ben David (COO), Dr. Vered Kivity (VP Regulatory & Clinical Affairs), Dr. Atara Novak (VP R&D), Dr. Corinne Chemouny (VP Quality Assurance), Dr. Tomer Bronshtein (VP Innovation & Corporate Development) and Meital Enbar, CPA (VP Finance).
- Prof. Nimrod Rozen, MD PhD - advisory board, orthopaedic trauma
- Prof. Edwin M. Horwitz, MD PhD - advisory board, Emory University
- Gil Shapira - board, life-science facilities
- Benjamin Shafir - board, strategy and finance
- Alon Ariel - board, life-sciences industry
- Margalit Assayag - board, management
Research partners
Bonus Biogroup collaborates with leading academic and research institutions. Recent partnerships include the Israel Institute for Biological Research (ricin-induced acute lung injury models), The Jackson Laboratory in the USA (humanised cytokine release syndrome model) and St. Catherine's Hospital in Croatia, alongside academic work at the Technion - Israel Institute of Technology and Emory University. Findings have been presented in Cytotherapy and the Journal of Oral and Maxillofacial Surgery.
Investor information
Bonus Biogroup is listed on the Tel Aviv Stock Exchange under the ticker BONS. The company publishes its pipeline updates, regulatory milestones and company presentation through its investor relations section, and accepts investor enquiries through the contact form on its site.
Important: the product candidates described here are investigational and have not been approved by the FDA or any other regulatory authority for commercial use. Clinical trials are ongoing to evaluate their safety and efficacy.
Contact
Head office
Matam Advanced Technology Park
P.O.B 15143
Haifa 31905, Israel
Phone
+972 (0)73 206 7104
info@bonus-bio.com
Website
bonus-bio.com
Areas of operation
Laboratory & GMP manufacturing
Science & pipeline
Clinical programme & patient outcomes
Locations and branches
Main location
Matam Advanced Technology Park, P.O.B 15143, Haifa
Contact details
Address
Matam Advanced Technology Park, P.O.B 15143
Haifa
Phone
+972-73-206-7104
info@bonus-bio.com
Website
bonus-bio.com
Social networks
Main areas of activity
Reviews
No reviews yet